← Back to Clinical Trials
Recruiting NCT07593313

NCT07593313 Treatment of Post-Stroke Central Pain

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07593313
Status Recruiting
Phase
Sponsor Nanchong Central Hospital
Condition Central Post-Stroke Pain
Study Type INTERVENTIONAL
Enrollment 80 participants
Start Date 2024-01-01
Primary Completion 2026-08-01

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type INTERVENTIONAL
Interventions
stSCS+Gabapentin or Pregabalin (with optional Duloxetine or Amitriptyline)Gabapentin or Pregabalin (with optional Duloxetine or Amitriptyline)

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 80 participants in total. It began in 2024-01-01 with a primary completion date of 2026-08-01.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

To evaluate the short-term analgesic efficacy of stSCS combined with pharmacotherapy compared with pharmacotherapy alone in patients with CPSP, measured by Numerical Rating Scale (NRS) score immediately after treatment.

Eligibility Criteria

Inclusion Criteria: * Diagnosis of central post-stroke pain (CPSP) according to the International Association for the Study of Pain (IASP) criteria * Clear history of stroke confirmed by cranial CT or MRI * Pain occurring after stroke and distributed in body parts corresponding to central nervous system injury * Pain with neuropathic characteristics (e.g., burning sensation, electric shock sensation, needle prick sensation) * Pain not explained by other causes * Age ≥ 18 years * Pain duration ≥ 3 months * Baseline pain Numerical Rating Scale (NRS) score ≥ 4 points * Complete clinical data with follow-up time ≥ 6 months Exclusion Criteria: * History of chronic pain before stroke * Severe cognitive impairment that prevents cooperation with pain assessment (Mini-Mental State Examination, MMSE \< 15 points) * Contraindications to spinal cord stimulation (SCS), such as coagulation disorders, active infections, or mental diseases that prevent cooperation * Malignant tumors or other severe organic diseases with expected survival \< 1 year

Contact & Investigator

Central Contact

Zhenguo Gao

✉ gaozhenguo0822@163.com

📞 18404999336

Frequently Asked Questions

Who can join the NCT07593313 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Central Post-Stroke Pain. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07593313 currently recruiting?

Yes, NCT07593313 is actively recruiting participants. Contact the research team at gaozhenguo0822@163.com for enrollment information.

Where is the NCT07593313 trial being conducted?

This trial is being conducted at Nanchong, China.

Who is sponsoring the NCT07593313 clinical trial?

NCT07593313 is sponsored by Nanchong Central Hospital. The trial plans to enroll 80 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology